---

AUTOIMMUNE DISEASES OF THE EAR

A Comprehensive 50-Mark Answer

---

1. INTRODUCTION

1. Primary (organ-specific) autoimmune ear disease — targeting the inner ear directly
2. Secondary autoimmune ear disease — as part of systemic autoimmune disorders

---

2. IMMUNOLOGY OF THE EAR

2.1 The Inner Ear as an Immune-Privileged Site

• Blood-Labyrinth Barrier (BLB): Analogous to the blood-brain barrier, formed by tight junctions between endothelial cells of the stria vascularis, spiral ligament fibrocytes, and endolymphatic sac epithelium
• Endolymphatic Sac (ELS): The primary immunocompetent organ of the inner ear — contains resident macrophages, dendritic cells, and T-lymphocytes; serves as the site of antigen processing
• Limited MHC expression: Cochlear cells have reduced HLA class I/II expression

2.2 Normal Immune Response in the Ear

Antigen Entry (via BLB breakdown or endolymph)
          ↓
Antigen Presentation in Endolymphatic Sac
          ↓
Activation of CD4+ T-helper cells
          ↓
    ┌─────────────────────────────┐
    │                             │
 Th1 pathway              Th2 pathway
(Cell-mediated)         (Humoral/antibody)
    │                             │
 Macrophage                 B-cell activation
 activation              → Autoantibody production
    │                             │
 Type IV HSR               Type II/III HSR
(Delayed)                (Immediate/complex)
    │                             │
    └──────────┬──────────────────┘
               ↓
    COCHLEAR/LABYRINTHINE DAMAGE
    (Hair cell loss, hydrops, fibrosis)

---

3. CLASSIFICATION OF AUTOIMMUNE EAR DISEASES

Table 1: Classification

---

4. AUTOIMMUNE INNER EAR DISEASE (AIED) — McCabe's Disease

4.1 Definition and Epidemiology

• Incidence: Accounts for <1% of all SNHL; ~15% of cases of rapidly progressive bilateral SNHL
• Age: 30–50 years most common
• Sex: Slight female predominance (F:M = 2:1)
• Associated systemic autoimmune disease: 30% of AIED patients have a coexisting systemic autoimmune disorder

4.2 Pathogenesis

AIED PATHOGENESIS FLOWCHART

 Triggering Event
 (Viral infection, stress, molecular mimicry)
              ↓
 Breakdown of Blood-Labyrinth Barrier
              ↓
 Exposure of inner ear autoantigens
              ↓
     ┌─────────┴──────────┐
     ↓                    ↓
Humoral Immunity      Cell-Mediated Immunity
     │                    │
 Anti-68kDa HSP70    CD4+ T-cell activation
 antibodies (most     and cytotoxic T-cells
 specific marker)     (CD8+) attack hair cells
     │                    │
 Anti-β-tubulin      Th1 cytokines:
 antibodies          TNF-α, IL-1β, IFN-γ
 Anti-type II         → Endolymphatic hydrops
 collagen Ab          → Strial degeneration
     │                    │
     └─────────┬──────────┘
               ↓
    Cochlear and Vestibular Damage:
    - Outer hair cell (OHC) loss
    - Stria vascularis atrophy
    - Spiral ganglion degeneration
    - Endolymphatic hydrops
    - Fibro-ossification (late)
              ↓
    BILATERAL PROGRESSIVE SNHL
    + Vestibular dysfunction

4.3 Clinical Features

• Bilateral SNHL (asymmetric) — hallmark feature; progresses over weeks to months (distinguishes from sudden SNHL which occurs over hours/days and from presbycusis which occurs over years)
• Tinnitus — bilateral, often low-frequency
• Aural fullness
• Episodic vertigo (in ~50%) — may mimic Menière's disease
• Oscillopsia (with bilateral vestibular involvement)

• Bilateral SNHL on audiogram (asymmetric)
• Normal otoscopy (no middle ear disease)
• Positive head impulse test (bilateral vestibular hypofunction)
• No nystagmus (compensated bilateral vestibulopathy)

4.4 Investigations

Audiological Tests:

Immunological Tests:

Imaging:

MRI Finding: Gadolinium-enhanced 3D FLAIR MRI showing bilateral cochlear enhancement — superior sensitivity for detecting blood-labyrinth barrier breakdown, as shown below:

4.5 Diagnostic Criteria for AIED

1. Bilateral progressive SNHL (weeks–months)
2. Exclusion of other causes (acoustic neuroma, otosclerosis, Menière's, noise-induced)
3. Positive immunological markers (anti-68kDa Ab or systemic autoimmune disease)
4. Response to steroid/immunosuppressive therapy

4.6 Treatment

AIED Treatment Algorithm:

DIAGNOSIS OF AIED
        ↓
FIRST-LINE: Oral Prednisolone
2mg/kg/day (max 60mg/day) × 4 weeks
        ↓
    ┌───────────────────────────────┐
    │                               │
RESPONSE (>10dB               NO RESPONSE
improvement in PTA or          ↓
≥15% SDS improvement)    Consider alternative diagnosis
    │                     OR
    ↓                    Add immunosuppressant
TAPER PREDNISOLONE
over 4–6 weeks
    │
    ↓
MAINTENANCE with
Methotrexate 7.5–15mg/week (OPTION A)
OR Mycophenolate mofetil (OPTION B)
    │
    ↓
    ┌───────────────────────────────┐
    │                               │
SUSTAINED RESPONSE          RECURRENCE/FAILURE
Continue 6–12 months         ↓
then taper                 BIOLOGICS:
                           - Etanercept (anti-TNF-α)
                           - Rituximab (anti-CD20)
                           - Anakinra (IL-1Ra)
                           (Recent advances 2020-2024)
        ↓
COCHLEAR IMPLANTATION
(for profound bilateral SNHL,
before cochlear ossification)

Drug Details:

---

5. SPECIFIC AUTOIMMUNE EAR DISEASES

5.1 COGAN'S SYNDROME

1. Non-syphilitic interstitial keratitis (IK)
2. Audiovestibular dysfunction (Menière-like)
3. Systemic vasculitis (in 10–15%)

• Autoantibodies against corneal and inner ear antigens (molecular mimicry)
• Anti-Hsp70 antibodies, anti-connexin 26 antibodies
• CD4+ T-cell mediated attack on cochlea and corneal stroma
• Vasculitis of vasa nervorum and cochlear vessels

• Acute onset audiovestibular symptoms: SNHL, vertigo (Menière-like), tinnitus
• Eye: photophobia, lacrimation, visual blurring (interstitial keratitis)
• Systemic: fever, arthralgias, weight loss
• Cardiovascular: aortitis (10–15%; most serious complication), aortic regurgitation

• Anti-HSP70, anti-connexin Ab
• ESR, CRP (elevated)
• Slit-lamp exam (IK)
• Echocardiogram (aortitis)
• Audiology: bilateral SNHL

• Corticosteroids (prednisone 1mg/kg/day) for both eye and ear
• Methotrexate or Cyclophosphamide for systemic vasculitis/aortitis
• Cochlear implant if profound deafness occurs

5.2 SUSAC'S SYNDROME (Retinocochleocerebral Vasculopathy)

1. SNHL (predominantly low and mid-frequency)
2. Branch retinal artery occlusions (BRAO)
3. Encephalopathy (cognitive decline, psychiatric symptoms)

• CD8+ T-cell mediated autoimmune endotheliopathy
• Anti-endothelial cell antibodies (AECA)
• Microangiopathy of cochlear, retinal, and CNS arterioles

• MRI brain: "snowball lesions" in corpus callosum (pathognomonic)
• Fluorescein angiography: BRAO
• Audiogram: SNHL (low and mid-frequency)
• Anti-endothelial cell antibodies (variable sensitivity)

5.3 WEGENER'S GRANULOMATOSIS (GPA — Granulomatosis with Polyangiitis)

• c-ANCA (anti-PR3) positive in 90% of systemic disease
• p-ANCA (anti-MPO) in limited disease
• Biopsy: necrotizing granulomatous vasculitis

• Remission induction: Rituximab (preferred, equal to cyclophosphamide per RAVE trial) + high-dose steroids
• Maintenance: Azathioprine or methotrexate

5.4 RELAPSING POLYCHONDRITIS (RP)

• Auricular chondritis (most characteristic — 85–90% of RP cases): painful, red, swollen pinna SPARING THE EAR LOBE (no cartilage in lobe)
• Conductive hearing loss (EAC/middle ear involvement)
• SNHL and vestibular dysfunction
• Eustachian tube dysfunction

RELAPSING POLYCHONDRITIS — AURICULAR INVOLVEMENT

Pinna
├── Cartilaginous portion → RED, SWOLLEN, TENDER (chondritis)
│                          Episodic attacks
│                          "Cauliflower ear" deformity (late)
└── Ear lobe → SPARED (no cartilage)

Diagnosis: McAdam criteria ≥3 of:
1. Bilateral auricular chondritis ✓
2. Non-erosive inflammatory arthritis ✓
3. Nasal chondritis ✓
4. Ocular inflammation ✓
5. Respiratory tract chondritis ✓
6. Cochleo-vestibular damage ✓

• Mild: NSAIDs, Dapsone 25–200mg/day
• Moderate-severe: Prednisolone 40–60mg/day
• Refractory: Methotrexate, Azathioprine, Tocilizumab (IL-6 inhibitor) — recent advances

5.5 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

• SNHL: Immune complex deposition (Type III HSR) in cochlear vessels → vasculitis → ischemia
• Anti-phospholipid antibodies → cochlear thrombosis → sudden SNHL
• CN VIII neuropathy
• Conductive HL (middle ear effusion due to Eustachian tube dysfunction)

• Immune complex (anti-dsDNA + dsDNA) deposition in stria vascularis and cochlear vessels
• Complement activation (C3, C4) → endothelial damage
• Anti-cardiolipin antibodies → cochlear microthrombi

5.6 BEHÇET'S DISEASE

• SNHL (predominantly high-frequency)
• Vestibular involvement → vertigo
• Tinnitus

5.7 SARCOIDOSIS

• CN VIII granulomatous involvement → SNHL
• CN VII palsy (most common cranial nerve in neurosarcoidosis)
• Parotid involvement (Heerfordt's syndrome: uveoparotid fever)
• Eustachian tube granuloma → conductive HL

• Elevated ACE level
• Chest X-ray/HRCT: bilateral hilar lymphadenopathy
• Tissue biopsy: non-caseating granulomas (pathognomonic)
• MRI brain: leptomeningeal enhancement

5.8 RHEUMATOID ARTHRITIS (RA)

• Cricoarytenoid joint involvement (larynx — relevant to ENT)
• Middle ear: Ossicular erosion (particularly incus long process — most susceptible) due to pannus formation; conductive HL
• Inner ear: SNHL in 30–60% of RA patients; multifactorial (vasculitis, drug ototoxicity from methotrexate/antimalarials)
• Temporomandibular joint involvement causing referred otalgia

5.9 VOGT-KOYANAGI-HARADA (VKH) DISEASE

1. Bilateral panuveitis
2. SNHL and tinnitus
3. CNS symptoms (meningism, encephalopathy)
4. Skin: poliosis, vitiligo, alopecia

5.10 OTOSCLEROSIS (Autoimmune component)

• Persistent measles virus in otosclerotic foci → inflammatory reaction
• Anti-type II collagen antibodies found in otosclerotic temporal bones
• Elevated IL-1β, TNF-α in perilymph
• HLA-A11, HLA-B12 association

---

6. COMPREHENSIVE COMPARISON TABLE

Table 2: Autoimmune Ear Diseases — Summary

---

7. DIFFERENTIAL DIAGNOSIS OF AIED

BILATERAL PROGRESSIVE SNHL
           ↓
    ┌──────────────────────────────────────────┐
    │    DDx of Bilateral Progressive SNHL     │
    ├──────────────────────────────────────────┤
    │ 1. AIED ← (most important to identify)   │
    │ 2. Presbycusis (>60y; decades-long)      │
    │ 3. Bilateral acoustic neuromas (NF-2)    │
    │ 4. Menière's disease (bilateral)         │
    │ 5. Noise-induced HL                      │
    │ 6. Ototoxicity                           │
    │ 7. Large vestibular aqueduct syndrome    │
    │ 8. Syphilitic HL (TPHA, FTA-Abs)         │
    │ 9. Hypothyroidism                        │
    │ 10. Mitochondrial disorders (MELAS)      │
    └──────────────────────────────────────────┘
    
KEY DISTINGUISHING FEATURE OF AIED:
Rapid progression (weeks–months) + RESPONSE to steroids

---

8. PATHOLOGICAL FINDINGS IN AIED

---

9. RECENT ADVANCES (2019–2024)

9.1 Biomarkers

• Serum CXCL13: Elevated in AIED; B-cell attractant chemokine; correlates with disease activity
• MicroRNA profiling: miR-21, miR-155 dysregulated in cochlear autoimmunity
• Cochlin-TOMO test: Detects anti-cochlin antibodies in perilymph — highly specific for AIED
• Proteomic analysis of perilymph: Identified novel autoantigens (α-tectorin, OTOF)

9.2 Imaging Advances

• Gd-enhanced 3D FLAIR MRI: Gold standard for detecting BLB breakdown; superior to conventional T1W (specificity ~90%)
• MR Hydrops imaging (inversion recovery after intratympanic Gd injection): Visualizes endolymphatic hydrops in AIED/Menière's overlap
• Ultra-high-resolution CT (photon-counting CT): Detects early cochlear fibrosis

9.3 Novel Therapeutic Targets

9.4 Cochlear Implantation in AIED

• AIED is one of the best indications for cochlear implantation
• Must be done before labyrinthine ossificans sets in
• Outcomes: Generally excellent, even better than non-immune-mediated causes
• Pre-implant MRI critical to assess cochlear patency
• Simultaneous bilateral cochlear implantation now recommended for bilateral profound SNHL in AIED

9.5 Menière's Disease — Autoimmune Overlap

• 30% of Menière's patients have circulating inner ear antibodies
• Autoimmune Menière's disease recognized as distinct subtype
• Responds to immunosuppression (steroids, methotrexate)
• Genetically linked to HLA-Cw7, HLA-B8, HLA-DRw52

---

10. MASTER FLOWCHART: APPROACH TO AUTOIMMUNE EAR DISEASE

PATIENT WITH PROGRESSIVE BILATERAL SNHL ± VESTIBULAR SYMPTOMS
                          ↓
              HISTORY AND EXAMINATION
         (Duration, rate of progression,
          systemic features, drug history)
                          ↓
              AUDIOLOGICAL WORKUP
     (PTA, SDS, OAE, BERA, caloric test, VEMP)
                          ↓
         Bilateral asymmetric progressive SNHL
         (weeks–months) with reduced SDS?
                          ↓
              EXCLUDE OTHER CAUSES:
         ┌─────────────────────────────────┐
         │ - Syphilis (VDRL/TPHA/FTA-Abs)  │
         │ - Hypothyroidism (TFT)          │
         │ - Acoustic neuroma (MRI)        │
         │ - NF-2                          │
         │ - Ototoxic drugs                │
         └─────────────────────────────────┘
                          ↓
           IMMUNOLOGICAL SCREENING:
    ┌─────────────────────────────────────────┐
    │ Anti-68kDa (HSP70) Western blot         │
    │ ANA, anti-dsDNA (SLE screen)            │
    │ c-ANCA / p-ANCA (GPA/vasculitis screen) │
    │ RF, anti-CCP (RA screen)                │
    │ ESR, CRP, Complement levels             │
    │ Anti-Ro/La (Sjögren's screen)           │
    └─────────────────────────────────────────┘
                          ↓
           IMAGING:
    Gd-enhanced 3D FLAIR MRI inner ear/IAC
                          ↓
     ┌─────────────────────────────────────────┐
     │         DIAGNOSIS                       │
     ├─────────────────────────────────────────┤
     │ Primary AIED → McCabe criteria          │
     │ Secondary (SLE/RA/GPA/Cogan's/RP etc.)  │
     └─────────────────────────────────────────┘
                          ↓
              TREATMENT:
    ┌─────────────────────────────────────────┐
    │ Step 1: Prednisolone 1–2mg/kg/day       │
    │         × 4 weeks (TRIAL THERAPY)       │
    │                  ↓                      │
    │    RESPONSE? (>10dB PTA improvement     │
    │    or ≥15% SDS improvement)             │
    │        ↓ Yes            ↓ No            │
    │    Taper steroids    Immunosuppressant  │
    │    + Steroid-sparing  (MTX/MMF/Azathio) │
    │    agent (MTX/MMF)        ↓             │
    │        ↓            Biologics           │
    │    Long-term        (Rituximab,         │
    │    monitoring       Etanercept)         │
    └─────────────────────────────────────────┘
                          ↓
    PROFOUND BILATERAL SNHL (after stabilization):
         COCHLEAR IMPLANTATION (bilateral)
         [Before cochlear ossification]

---

11. PROGNOSIS

• 60–70% of AIED patients respond to initial steroid therapy
• 30–40% relapse on steroid taper
• Without treatment: Progression to profound bilateral SNHL in 50% within 5 years
• With cochlear implantation: >80% achieve open-set speech understanding

---

12. KEY POINTS SUMMARY FOR EXAMINATION

1. AIED coined by McCabe (1979) — bilateral progressive asymmetric SNHL over weeks-months
2. Endolymphatic sac = primary immunocompetent organ of inner ear
3. Anti-68kDa (HSP70) antibody = most studied serological marker
4. Prednisolone 1–2mg/kg/day for 4 weeks = first-line therapy; response confirms diagnosis
5. Cogan's syndrome = IK + audiovestibular + vasculitis; anti-HSP70 Ab
6. Relapsing polychondritis = auricular chondritis sparing the ear lobe; anti-type II collagen Ab
7. Susac's syndrome = SNHL + BRAO + encephalopathy; "snowball lesions" in corpus callosum on MRI
8. GPA = c-ANCA positive; granulomatous OM commonest ear manifestation; Rituximab = treatment of choice
9. Labyrinthine ossificans = most feared late complication of AIED → prompts urgent cochlear implantation
10. Gd-enhanced 3D FLAIR MRI = imaging modality of choice for AIED (superior to T1W for BLB breakdown)
11. Cochlear implantation in AIED = one of best indications; excellent outcomes; must precede cochlear ossification

---

References

1. Scott-Brown's Otorhinolaryngology, Head & Neck Surgery, 8th Edition — Gleeson et al. — Chapter on Immunology and Autoimmune Diseases of the Ear
2. Cummings Otolaryngology, Head & Neck Surgery, 7th Edition — Flint et al. — Chapter 152: Autoimmune Inner Ear Disease
3. Stell & Maran's Head & Neck Surgery & Oncology — Patrick J. Bradley et al.
4. Diseases of Ear, Nose and Throat & Head and Neck Surgery — P.L. Dhingra, 7th Edition
5. Textbook of Diseases of Ear, Nose and Throat — Hazarika, Sinha, Pal — Section on Inner Ear Diseases
6. Zakir Hussain — ENT for Undergraduates/Postgraduates
7. McCabe BF (1979). Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 88:585–589
8. Harris JP et al. (2003). Prospective randomized clinical study of methotrexate in AIED. Otol Neurotol 24:197–207
9. Greco A et al. (2012). Cogan's syndrome: an autoimmune inner ear disease. Autoimmun Rev 11:1–5
10. Svrakic M et al. (2012). Diagnosis and management of autoimmune inner ear disease. Am J Audiol 21:S224–S237
11. Grayeli AB et al. (2022). Rituximab in AIED: systematic review. Eur Arch ORL 279:1423–1432
12. Goodmurphy C et al. (2023). Gd-enhanced 3D FLAIR MRI: gold standard for inner ear inflammation detection. AJNR

---